Tissue Repair gains TGA approval for cosmetic wound healing gel

Biotechnology company Tissue Repair will widen commercialisation activities following receipt of Therapeutic Goods Administration approval for its TR Pro+ would healing gel.

TR Pro+ is already on the market where it is sold as a cosmetic, with TGA approval allowing the company to to more broadly promote its scientific and clinical data.

Currently it is sold as a post procedural topical gel to accelerate healing and improve skin quality following cosmetic procedures.

Sales of the gels reached a new high in June, with Q3 revenue 130 percent above the prior quarter – the gels are sold in 160 clinics.

Tissue Repair told investors: “Importantly, securing general claims around skin healing, repair and regeneration will allow the company to significantly expand the indications that it can market the product for including acute wounds, and a broader range of derm conditions.”

TR Pro+ contains the active ingredient glucoprime which is derived from yeast, and has been approved in 10g and 50g tubes, as well as 3g sachets.

TR Pro+ is based on the core technology platform behind the company’s lead drug candidate TR987 for the treatment of venous leg ulcers.

Tissue Repair will shortly begin a Phase 3 clinical trial programme for TR987 in chronic wounds.

The Co-Founder and Executive Director of Tissue Repair, Tony Charara (pictured) will shortly provide a more detailed update presentation on the approval and the company’s strategy.

Picture: Tissue Repair/Tony Charara, Co-Founder and Executive Director